Trailing-twelve-month (TTM) revenue is $1.67 Million with a year-over-year growth of (60.77%). Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $260,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-10 |
| Q4 FY2025Period ended 2025-12-31 | $1,139,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-26 |
| Q1 FY2026Period ended 2026-03-31 | $32,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-13 |
| Q2 FY2026Period ended 2026-06-30 | $239,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10 |
| TTM revenue | $1,670,000 |
Current P/S: $117,374,757 market capitalization ÷ $1,670,000 TTM revenue = 70.28x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T15:05:09.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $239000.00.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T15:07:08.499Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|
| Laboratory Services | N/A | $4M |
| Pharma Services | $2M | N/A |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|
| Asia Pacific | $145,000 | N/A |
| Europe | N/A | $24,000 |
| GERMANY | $18,000 | N/A |
| UNITED STATES | $2M | $4M |
$1.67M
$1.67 Million
(60.77%)
vs. $4.26M a year ago (TTM)
+27.24%
5 Year compound annual growth rate
1 Year
(60.77%)
3 Year
+14.89%
5 Year
+27.24%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $4.05M | +$2.17M | +115.58% |
| 2024 | $1.88M | +$378,000 | +25.15% |
| 2023 | $1.50M | +$545,000 | +56.89% |
| 2022 | $958,000 | ($1.24M) | (56.41%) |
| 2021 | $2.20M | +$982,000 | +80.76% |
TTM Growth
(60.77%)
3-Year CAGR
+14.89%
5-Year CAGR
+27.24%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 21 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T15:07:08.499Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
